STOCK TITAN

Integra LifeSciences Holdings (IART) Stock News

IART NASDAQ

Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.

Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.

Rhea-AI Summary

Integra LifeSciences (Nasdaq: IART) will present at the 2026 UBS Global Healthcare Conference on November 9, 2026. Chief Financial Officer Lea Knight will deliver the presentation at 2:45 p.m. ET. A live webcast will be available on the company’s investor relations website under EVENTS & PRESENTATIONS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences (IART) will participate in the CNS Annual Meeting, taking place October 31–November 4, 2026, in Washington, D.C. The company will offer interactive education and procedural skills activities at Booth 341. A mobile hands-on laboratory on November 3 will provide product training in dural repair, tissue resection and other areas of neurosurgical care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences (Nasdaq: IART) reported third-quarter 2026 revenue of $411.2 million, with growth despite flood-related disruption at its Cincinnati facility. Revenue rose 2.3% year over year, or 2.5% organically, including an approximately $7 million flood impact. GAAP diluted earnings were $0.19 versus a $0.07 loss; adjusted diluted earnings rose to $0.59 from $0.54. Gross margin fell to 51.0% from 51.5%.

Specialty Surgery revenue grew 3.9%, while Tissue Reconstruction declined 2.2%. Operating cash flow reached $96.0 million, and consolidated total leverage fell to 3.8x. On October 19, Integra completed a $2.1 billion refinancing extending debt maturities. The company maintained its October 2 full-year outlook for revenue of $1.634 billion–$1.654 billion and adjusted diluted earnings of $2.30–$2.40, while expecting fourth-quarter reported revenue to decline 5.2%–0.5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
Rhea-AI Summary

Integra LifeSciences Holdings (NASDAQ: IART) completed a refinancing that included a private offering of $450.0 million in senior secured notes. The notes carry a 9.500% interest rate and mature in 2033.

The amended and restated credit facility totals approximately $1.65 billion: a $600 million revolving facility and a $600 million term loan A, each with a five year maturity, plus a $450 million term loan B with a seven year maturity. All three facilities are senior secured. Net note proceeds and credit facility borrowings refinanced the existing credit facility and paid transaction fees and expenses. The notes are guaranteed by wholly-owned domestic subsidiaries that guarantee the credit facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences (IART) will showcase its ear, nose and throat portfolio at the AAO-HNSF Annual Meeting, October 17–20 in Los Angeles. Integra also sponsors the Otosclerosis Study Group, where Seilesh C. Babu will present investigator-initiated research on October 17. The study examines Eustachian tube balloon dilation performed alongside surgery for chronic ear disease. Attendees can visit Booth 1400 for ACCLARENT AERA training and certification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary

Integra LifeSciences Holdings (IART) priced $450 million of senior secured notes as part of a broader refinancing transaction. The notes carry a 9.500% rate and mature in 2033. Closing is expected on or about October 19, 2026. The company intends to combine net proceeds with borrowings under new credit facilities to refinance existing credit facilities and pay related fees and expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none
Rhea-AI Summary

Integra LifeSciences (NASDAQ: IART) will release third-quarter 2026 financial results before the market opens on October 21, 2026.

Management will host a conference call at 8:30 a.m. ET that day. A live webcast and a replay following the call will be available on the Investors section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences earnings date
-
Rhea-AI Summary

Integra LifeSciences (IART) lowered its full-year 2026 revenue and adjusted earnings guidance as flooding disrupted production at its Cincinnati facility.

Preliminary, unaudited third-quarter revenue is expected at approximately $410 million to $412 million, with adjusted earnings per diluted share of $0.55 to $0.59. Integra estimates flooding reduced third-quarter revenue by approximately $7 million and expects a fourth-quarter impact of approximately $15 million to $20 million.

Full-year revenue guidance fell from $1.654 billion–$1.695 billion to $1.634 billion–$1.654 billion; adjusted earnings per diluted share guidance fell from $2.40–$2.50 to $2.30–$2.40. Integra expects operating cash flow greater than $85 million in the third quarter and approximately $190 million to $200 million for the year, with full manufacturing operations returning in the second quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.19%
Tags
none
-
Rhea-AI Summary

Integra LifeSciences (IART) launched a proposed $600 million senior secured Term Loan B as part of a broader refinancing transaction. The loan would have a seven-year term. The company intends to use net proceeds, together with other financing sources, to refinance certain existing debt and pay associated fees and expenses. Completion is expected alongside refinancing of its existing capital structure, subject to market and other customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.19%
Tags
none
Rhea-AI Summary

Integra LifeSciences (IART) enrolled the 100th patient in its AERA Pediatric Registry, which is evaluating the AERA balloon dilation system.

Launched in July 2025, the prospective, multicenter observational registry plans to enroll 300 patients ages eight and older with obstructive Eustachian tube dysfunction at U.S. sites. It is designed to gather evidence on AERA’s clinical performance in routine care. AERA received FDA clearance for use in patients ages eight and older in December 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none

FAQ

What is the current stock price of Integra LifeSciences Holdings (IART)?

Integra LifeSciences Holdings (IART) last closed at $13.98.

What is the market cap of Integra LifeSciences Holdings (IART)?

The market cap of Integra LifeSciences Holdings (IART) is approximately $1.1B.